Detailed Narrative
EscharEx Phase III VALUE Study Update
Enrollment for the global Phase III VALUE study in venous leg ulcers has progressed more gradually than anticipated due to ancillary-related regulatory adjustments in Europe, which are now completed, and participation challenges for older VLU patients. The company has implemented patient assistance measures, including hotel reimbursements and transportation services, and expects to reach 40 active sites soon. Interim sample size reassessment and enrollment completion are projected by Q1 2027, with the protocol's daily wound assessment reflecting EscharEx's rapid action.
Expanding Chronic Wound Collaboration Network
Medline, a global leader in medical surgical and wound care products, has joined MediWound's collaboration network, which now includes major advanced wound care companies like Coloplast/Kerecis, Convatec, Essity, Mölnlycke, Solventum, B. Braun, and MIMEDX. This network reflects a growing recognition for effective, easy-to-use nonsurgical debridement solutions. Medline will specifically provide its Marathon skin protectant for the upcoming DFU Phase II study, aiming to protect healthy periwound tissue while EscharEx debrides the wound bed.
NexoBrid Commercial and Government Footprint
Vericel reported continued growth in ordering centers and total orders for NexoBrid in the US burn care market. A new 10-year BARDA contract, valued at up to $197 million, was awarded to Vericel to support NexoBrid procurement, vendor management inventory services, potential blast trauma indication development, and next-generation manufacturing. This contract builds on approximately $138 million already received from BARDA, solidifying NexoBrid's strategic importance for mass casualty burn response and national preparedness.
Manufacturing Facility Expansion and Regulatory Progress
MediWound is advancing its expanded NexoBrid manufacturing facility towards commercial readiness. Following an EMA pre-audit, several operational modifications were identified and are currently being implemented, with completion expected in the second half of 2026. These modifications are operational in nature and not related to product quality or safety. An FDA inspection for the facility is planned for early 2027, contingent on finalization with the EMA.
EscharEx Pipeline Expansion and Differentiation
Beyond the primary VLU study, MediWound is expanding EscharEx into additional chronic wound indications, with a Phase II study in diabetic foot ulcers and an investigator-initiated trial in pressure ulcers both planned for the second half of 2026. The company is also conducting a head-to-head Phase II study versus collagenase (SANTYL) and other nonsurgical standard of care modalities to strengthen differentiation and support future market access discussions.
Impact of Medicare Physician Fee Schedule Changes on Wound Care Market
Recent changes to the Medicare Physician Fee Schedule have significantly reclassified skin substitutes, leading to an estimated 90% reduction in Medicare spending on these products, from $14 billion to $1.4 billion. This change is projected to shrink the overall US chronic wound care market from $18 billion down to $5.5 billion. This market shift is viewed as a substantial commercial opportunity for differentiated products like EscharEx, as it reduces competition from less regulated products and encourages a focus on higher-order regulatory approvals.